Gillette India FY26: 56% Profit Growth, but at What Multiple?

At a Glance

Gillette India posted consolidated FY26 numbers that stopped traffic. ₹3,100 Cr in sales, ₹654 Cr in net profit—a 56% profit jump on 39% revenue growth. EPS exploded to ₹200.80 from ₹128.17 a year prior. Operating profit margins stretched to a crisp 30.4%, up from 24.3% last year.

Trouble is, the stock trades at a 38.7× P/E. That’s the hook. A company firing on every cylinder, but priced like it’s already won the next decade.

The Tension: record profitability and margin expansion colliding with a valuation that leaves little room for stumble.

Introduction

Gillette India lives in an unusual pocket of corporate India—it’s a blue-chip grooming business owned 75% by Procter & Gamble, listed on the BSE, and quietly crushing it.

The grooming category in India (razors, blades, shaving prep) is mature, competitive, and consolidating. Electric toothbrushes, battery-powered and positioning-heavy, are scaling fast. Together, grooming (80% of sales) and oral care (20%) form a duopoly-ish market where Gillette holds the strongest hand.

FY26 was the year management turned up the volume on what they call the “Integrated Growth Strategy”—focused portfolio, margin discipline, relentless productivity, and a willingness to disrupt themselves. The financial results show what that playbook delivers when execution sticks. The valuation suggests investors have already factored in perfection for the next five years.

Business Model: WTF Do They Even Do?

Gillette India makes and sells what you run across your face or put in your mouth.

Grooming (80% of sales): Think razors, blades, shaving creams, aftershave. Brands include Gillette Guard (entry-level, mass-market), Gillette Mach3 (mid-premium), Gillette Fusion (premium), Venus (women’s razors), and Braun (electric). The competitive battleground sits between cheap and premium—Gillette owns the top shelf, but the real money sits in high-volume systems that keep customers returning every few weeks for replacement blades.

Oral Care (20% of sales): Electric toothbrushes under Oral-B. The category is small but growing. Management sees upside in powering toothbrush adoption, especially among consumers trading up from manual brushes. Oral-B iO3 and Oral-B Vitality Pro are the recent pushes.

The Model’s Strength: High repeat-purchase frequency. Blades replace every two to three weeks. Toothbrush heads, every three months. Sticky revenue, sticky margins.

The Model’s Stress: category growth has been flat to low single-digit for years. The game is market share wars and price realization, not category expansion. Cheaper razors and competitive froth from startups erode the premium. Economic slowdowns hit personal grooming hard—men shave less, women stretch blade life, everyone uses less aftershave.

Financials Overview

Figures are consolidated, in ₹ crore.

The Story in One Chart: Sales grew 39%, but profit grew 56%. That gap—operating leverage in action—is the whole story. Margins expanded 600 bps (Operating Profit margin 24.3% → 30.4%), driven by productivity saves north of ₹40 crores, mix improvement toward higher-margin segments, and operational discipline that management calls “more than cost-cutting—it’s a more efficient way of operating every day.”

FY26 was also a transition year for the company: the accounting year flipped from Jul–Jun to Apr–Mar mid-cycle, complicating YoY comparisons. The 9-month stretch from Jul 2024 to Mar 2025 saw ₹2,235 Cr in sales and ₹418 Cr in profit—still growing, but the new FY starting Apr 2025 reset the clock.

What Management Said: On the concall in Jun 2025, management framed FY26 results as proof of concept for the Integrated Growth Strategy firing on “all cylinders.” They highlighted the Guard franchise gaining 5 million new consumers year-over-year, Mach3 upgrades resonating (“three anti-friction blades”), and Oral-B Power doubling its business in three years. The tone: momentum, not complacency.

Valuation Discussion: Fair Value Range (Educational Only)

What follows is an educational look at what the numbers imply — not a price target, and not advice.

FY26 Annualised Metrics:

• Reported EPS: ₹200.80 (full year, no multiplication)
• Current Price (CMP): ₹7,763
• Current P/E: 38.7×

Method 1: P/E Multiples

Peer median P/E across FMCG: ~39–40×. Gillette trades at the peer median (38.7×), but peers vary: Godrej Consumer at 50×, Dabur at 39×, Colgate at 40×, P&G Hygiene at 35×.

A 38–42× P/E band on ₹200.80 EPS suggests:

• Lower band (38×): ₹7,630 Cr
• Midpoint (40×): ₹8,032 Cr
• Upper band (42×): ₹8,434 Cr

Range: ₹7,630–8,434 per share

Method 2: EV/EBITDA

FY26 EBITDA = Operating Profit + Depreciation + Interest = 943.43 + 78.54 + 12.06 = ₹1,034 Cr.

Peer median EV/EBITDA: ~25–27×. Gillette’s enterprise value sits at ₹25,030 Cr (market cap of ₹25,300 Cr minus net cash).

EV/EBITDA = 25,030 ÷ 1,034 = 24.2×

Peer range is 19× (Emami) to 108× (Colgate, an outlier). A normalized 22–26× multiple on ₹1,034 Cr EBITDA suggests:

• Lower band (22×): EV ₹22,748 Cr → ~₹7,000 per share
• Midpoint (24×): EV ₹24,816 Cr → ~₹7,600 per share
• Upper band (26×): EV ₹26,884 Cr → ~₹8,250 per share

Range: ₹7,000–8,250 per share

Method 3: DCF (Simplified)

Assume:

• FY26 PAT as baseline: ₹654 Cr
• Revenue growth: 12% CAGR next 5 years (vs. 39% this year; normalization expected)
• PAT margin sustainability: 21% (vs. 21.1% this year)
• Terminal growth: 3%
• Cost of capital (WACC): 10%

Year 1–5 projected PATs: ₹732, ₹821, ₹919, ₹1,030, ₹1,154 Cr Sum PV (5 yrs @ 10%): ₹3,862 Cr Terminal Value (Year 6 onwards): PAT₹1,154 × 1.03 ÷ (0.10 – 0.03) = ₹17,020 Cr; PV = ₹10,573 Cr Total Enterprise Value: ₹14,435 Cr Per Share: ~₹4,430 per share (implies net cash of ₹269 Cr factored)

This DCF is conservative. It anchors 12% growth, assumes no margin expansion, and uses a 10% WACC. Sensitivity: if growth reaches 15% CAGR or margins sustain 22%, the implied value per share shifts toward ₹6,500–7,500.

Range: ₹4,500–7,500 per share (with the range extending toward ₹8,000 if the underlying assumptions improve)

Synthesis: The three methods imply a fair value range of ₹7,000 to ₹8,500 under the specific assumptions stated above, with a midpoint around ₹7,750. The current price of ₹7,763 sits near that midpoint under these particular assumptions. This does not mean the price is “correct”—it means the math aligns if you accept the growth, margin, and discount-rate assumptions. If you do not accept these assumptions, the implied range changes materially. This is an educational exercise in valuation methodology, not a prediction.

This fair value range is for educational purposes only and is not investment advice.

What’s Cooking: News, Triggers, Drama

1. Bhiwadi Manufacturing Plant Headwind (Critical)

In mid-March 2026, Rajasthan State Pollution Control Board (RSPCB) refused to renew the Consent to Operate (CTO) and hazardous waste authorization for Gillette’s Bhiwadi facility (one of two manufacturing plants). The refusal came on February 18, but the company is exploring legal remedies. Outcome TBD. If the plant shuts or is forced to upgrade capex, margin risk is real.

2. Management Churn

Three material appointments/resignations in six months:

• May 27: CFO Srividya Srinivasan to resign June 30, 2026; Ashwath Rao appointed July 1.
• May 27: Krishnamurthy Iyer and Ghanashyam Hegde appointed as Directors.
• Dec 2024 onward: Multiple sales and HR transitions.

Clean transitions or signal of internal friction? Hard to say, but director-level moves suggest reshuffling, not crisis.

3. Final Dividend ₹60/share (Record Feb 2026)

FY26 dividend payout stayed measured at 30% of net profit (₹195.54 Cr ÷ ₹654 Cr). January interim dividend of ₹180/share (including ₹60 special) was paid Feb 2026. Final dividend of ₹60 was approved May 2026. Total FY26 payout: ₹240/share (120% if you include the special). This is generous but off the typical 65% payout ratio—special dividend signals confidence.

4. Portfolio Launches & Superiority Pushes

Management emphasized “five-vector superiority”: product, package, brand communication, retail execution, and value. Recent FY26 launches that showed up in the concall:

• Gillette Guard upgrade (chrome-platinum coating, rust protection)
• Mach3 refresh (anti-friction blades, adaptive technology)
• Oral-B iO3 (premium power brush at accessible price)
• Venus (improved pack communication)

Data-driven assortment and neighborhood analytics ensure the “right portfolio at the right stores.” Distribution expanded by a million stores in three years.

5. Quick Commerce Bet

E-commerce and quick commerce (Blinkit, Zepto) are now “not an add-on option but an integral part of the shopper habit.” Management is scaling presence and using occasion-based activation (Father’s Day, festivals) to acquire new users.

Balance Sheet

Figures are consolidated, in ₹ crore.

Validation: Assets = Liabilities ✓ per column.

What the Numbers Whisper:

• Cash & Bank balances: ₹475.63 Cr (FY24) → ₹419.14 Cr (FY25) → ₹269.26 Cr (FY26). Cash burned hard in FY26, likely from the ₹740 Cr financing outflow (see Cash Flow). Dividend payout and buyback activity? Not disclosed yet.
• Net Cash Position: ₹269 Cr cash minus ₹0.02 Cr borrowings = ₹269 Cr net cash. A small private bank’s war chest, just sitting.
• Receivables: ₹397.73 Cr (up from ₹274 Cr year prior). Days Sales Outstanding extended to 47 days (vs. 38 days prior)—slower collections, likely mix (more credit-based trade, quick commerce payment terms).
• Inventory: ₹519.64 Cr (up from ₹453.47 Cr). Days Inventory Outstanding at 167 days vs. 181 days prior—still bloated, but trending lighter.
• Fixed Assets: ₹304.30 Cr (down from ₹346.92 Cr). Capex remains minimal (management avails P&G global R&D, so minimal in-house capex).

The Real Story: An asset-light FMCG model, minimal debt, and a balance sheet that’s pure muscle. But working capital is creeping higher—receivables and inventory both grew in absolute terms while sales inflated. Margin expansion is doing heavy lifting.

Cash Flow: Sab Number Game Hai

Figures are consolidated, in ₹ crore (last 3 years).

Operating CF Story:

FY26 operating cash generation of ₹607 Cr is solid—CFO to Operating Profit ratio of 89% (vs. 103% prior year). The slight dip from prior-year 103% suggests working capital headwinds: receivables and inventory absorbed some operating cash. Margin expansion and profit growth still drove strong absolute cash, but the trend bears watching.

Investing CF: Minimal capex. ₹15.56 Cr outflow is maintenance only. This is the P&G playbook—R&D and capex centralized globally, India as a high-margin cash-generation machine.

Financing CF: ₹740 Cr outflow. Dividend payments of ₹195.54 Cr, plus potential share buyback or repatriation? Management hasn’t disclosed specifics, but the number is lumpy—well above typical dividend.

Free Cash Flow: ₹564 Cr in FY26 (Operating CF minus Capex). Converts to ₹17.31 per share in FCF yield. The stock’s CMP/FCF of 61.6× (per the screener data) is steep, but reflects the growth profile.

Ratios: Sexy or Stressy?

Deep Dive:

• ROE of 66.4% is the kind of number that makes textbooks jealous. Equity base is ₹946 Cr; PAT is ₹654 Cr. The math checks. But equity shrinks every year from dividends (no retained earnings culture), so the denominator effect inflates the ratio. Real earning power is being harvested, not reinvested.
• ROCE of 90.6% is surreal. ROCE = EBIT ÷ (Equity + Debt). With near-zero debt, it’s essentially EBIT ÷ Equity = ₹880 Cr (PBT + Tax + Interest) ÷ ₹946 Cr = ~93%. The company earns ₹0.93 per rupee of capital deployed. No moat is that durable—either the market is mispricing competitive intensity, or Gillette has an unassailable franchise. Likely the former (razors are commoditizing, electric toothbrushes are competitive), so the ratio is a peak-cycle artifact.
• PAT Margin of 21.1% is the best-in-class FMCG number. Operating leverage and productivity are real. The question: is it sustainable? If volume growth slows and competitive pressure resumes, this margin retreats.

P&L Breakdown: Show Me the Money

Figures are consolidated, in ₹ crore (last 3 years).

The Journey:

Sales took a step back in FY25 (the 9-month transition year), but FY26 roared back—3,100 Cr is the highest top line in the company’s history. Operating profit more than made up the decline: 30.4% OPM in FY26 is 600 bps wider than FY24. Net margin swelled from 15.6% to 21.1% in two years.

What Drove It?

1. Mix: Shift toward higher-margin premium razors (Mach3, Fusion) and the Guard uptrend into premium variants. Management said Guard “gained the trust of 5 million more consumers”—if higher-margin configurations drive that, mix benefit is real.
2. Productivity: ₹40 Cr in savings across “all spend buckets”—manufacturing efficiency, procurement leverage, A&P optimization.
3. Volume + Price: Revenue up 39% implies both volume growth (distribution expansion, quick commerce) and price realization (inflation pass-through, premiumization).

The Risk: FY26 benefited from a perfect storm—volume growth, mix shift, and cost discipline all lining up. If any leg falters (volume slows, mix reverts, cost inflation returns), margins compress faster than they expanded. The company carries no operational buffer.

Peer Comparison

Scorecard:

• Scale: Gillette ranks 5th by sales, but PAT is proportionally higher—net margin game is working.
• Valuation (P/E): Gillette at 38.7× sits median vs. peers (Emami 21×, Dabur 39×, Godrej 50×). Not cheap, not expensive.
• Profitability (ROE): Gillette’s 66.4% ROE is second only to P&G Hygiene (115%) and Colgate (83%). Ominous: those high-ROE peers are also expensive (P/E 35–40×). Market is pricing Gillette at a slight discount to peers with similar magic.
• Operating Margins: Gillette’s 30.4% OPM is the best among pure FMCG peers. Colgate is close (31%), but Colgate also has 40× P/E and 82% ROE—suggesting the market sees Gillette as more vulnerable.

The Implication: Gillette’s relative cheapness (38.7× vs. Colgate 40.5×) despite equal-or-better margins suggests the market harbors doubts about margin sustainability or category tailwinds. Fair, given razor commoditization.

Miscellaneous: Shareholding & Promoters

Promoter Structure: Two P&G vehicles—Procter & Gamble Overseas India B.V. (40.12%) and Gillette Diversified Operations Private Limited (34.88%)—own the entire 75%. No pledges, no concerns. The parent company is committed, no signs of exit.

Why It Matters: A 75% promoter stake removes M&A risk and governance red flags. The downside is that public float is tight (24.75%), so liquidity is a real constraint for large positions. DIIs and FIIs have been steady nibbling (DII fell from 12.08% in Jun 2024 to 9.25% now; FIIs rose from 0.71% to 4.36%). Likely reallocation within FMCG baskets.

Corporate Governance: Angels or Devils?

Auditors: BSE filing lists Bansal & Associates as statutory auditors. No red flags, no TDS disputes flagged in FY26.

Tax Headwind (Resolved): March 2024, the company changed its transfer pricing methodology, triggering an ₹8 Cr additional tax liability for FY26 but clearing ₹250+ Cr in contingent liabilities from prior years (FY14–15, FY16–17). Net positive reputationally and balance-sheet-wise.

Board & Management:

• New MD Kumar Venkatasubramanian appointed May 2024.
• Rohini Venkateswaran promoted to Executive Director Oct 2025.
• C.P. Gurnani (Independent Director) resigned January 2026.
• Srividya Srinivasan (CFO) resigning June 2026.

Signals: Board is actively reshuffling. Not alarming (happens), but the pace of director changes suggests either planned renewal or early-stage succession stress. Worth monitoring Q1 concall comments.

ESG & Environmental Risk: Bhiwadi plant CTO refusal is the live issue (see “What’s Cooking”). If RSPCB doesn’t renew, capex or relocation is forced. Baddi (Himachal) plant is the backup, but dual-plant manufacturing is optimal for cost and de-risking. Regulatory risk is material.

Industry Roast & Macro Context

The razors-and-blades category is in secular slow-motion decline globally. Indian grooming is no exception.

Category Pressure: Subscription shave services (Dollar Shave Club, Harry’s) disrupted the model in US/EU; in India, the model is adapting but bleeding volume. Manual grooming adoption is down in metros; e-commerce and direct-to-consumer startups are nibbling share with lower prices.

Electric Toothbrushes: The Bright Spot. Oral-B power brush doubling in three years is real. But it’s 20% of revenue and margins are lower than grooming. The category is young, adoption is concentrated in urban India, and price-sensitive consumers still prefer manual. Scaling power brushes requires consistent A&P and distribution, both capital-intensive.

Pricing Power Erosion: Over the past three years, inflation (input costs, logistics, wages) outpaced the company’s pricing ability. FY26 margins expanded despite this, but only because of productivity—not pricing. If inflation returns and productivity plateaus, margins compress.

Regulatory Risk: Eco-conscious governments globally are eyeing plastic reduction in packaging. Gillette’s throwaway blade cartridges and plastic packaging are targets. India’s regulatory environment is gentler today, but the trend is global.

Consumption Slowdown Headwind: Management acknowledged India’s economic growth “sharp slowdown vs. the past 3 years” to ~6.5%. Urban consumption is soft. Rural recovery is tentative. Grooming is discretionary—margin of first cut in tough times. Management is confident the strategy can “navigate difficulties,” but belief is not visibility.

Verdict: The category is mature, competitive, and politically/environmentally under pressure. Gillette’s dominance and margins are impressive, but built on an industry in slow structural decline. The multi-year grooming narrative is “harvest,” not “growth.”

EduInvesting Verdict

Gillette India is a textbook FMCG story: a global brand with local scale, pricing power, a loyal customer base, and a balance sheet that could weather a decade of disruption. FY26 results prove the “Integrated Growth Strategy” is operational—57 Cr in margin expansion, portfolio premiumization working, and 5+ million new Guard consumers showing momentum.

Here’s the honest reckoning: the company is executing near-perfectly in a category that’s running out of runway. Razors commoditize. Electric toothbrushes are lower-margin and competitive. Costs will eventually normalize and shrink the 300-bps margin gains of the past two years. The current P/E of 38.7× prices in years of high-single-digit growth and margin stabilization—not crash, but not exceptional.

Strengths:

• Fortress balance sheet; zero debt; ₹269 Cr net cash.
• 66% ROE, 90% ROCE; best-in-class FMCG profitability.
• Dominant market share in blades/razors; oligopolistic position.
• Productivity embedded in operating model, not one-off cuts.
• Dividend payer for 30+ years; shareholder-friendly capital allocation.

Weaknesses:

• Category in secular decline; volume growth increasingly difficult.
• Margin expansion appears cycle-peak; sustainability uncertain.
• Promotional intensity rising in grooming; price wars possible.
• Regulatory headwind (Bhiwadi plant CTO refusal); capex or relocation risk.
• Limited capex in R&D; innovation increasingly dependent on P&G global.
• Quick-commerce adoption requires constant A&P; profitability of channel TBD.

Opportunities:

• Electric toothbrush scaling in India; still 10% of oral care globally.
• Geographic expansion in South Asia (exports are only 5.5% of sales).
• Premium grooming (Mach3, Fusion) mix shift; higher-margin volume.
• Digital commerce maturation; direct-to-consumer potential.

Threats:

• Continued category volume erosion; industry-wide pricing wars.
• Private-label penetration in quick commerce.
• Macro consumption slowdown; discretionary spend cuts.
• Competitive intensity from new entrants (especially in electric tooth brushes).
• Sustained input inflation; productivity ceiling visible.

Final Reflection:

Gillette India trades at ₹7,763, implying a valuation anchored to low-to-mid single-digit growth, 20%+ PAT margins, and stable market share. The math would shift materially if category recovery materialized (unlikely) or margin expansion resumed (risky, given the recent run). Conversely, the numbers assume modest margin compression and steady volume—if competitive pressure intensifies or volume slows faster, the valuation math deteriorates.

What the numbers suggest investors are assessing is a high-quality FMCG cash machine with a dividend track record. Not a value play. Not a growth story. A steady cash compounder at fair pricing. The investment merit depends entirely on whether you believe (a) margins will hold at 20%+, (b) volume growth will remain low-single-digit, and (c) the category will continue its slow drift. None of this is certain.

The numbers are real. The execution is demonstrated. The valuation reflects current market expectations. Whether those expectations are justified depends on your own view of the category, margins, and competitive dynamics.